ClinicalTrials.gg
RecruitingNCT06002386Vsling IIIUpdated Oct 28, 2026

Vsling™ III: Clinical Evaluation of the Vsling™ Device for Ventricular Repair in Patients With Heart Failure

An interventional study of Vsling in HFrEF - Heart Failure With Reduced Ejection Fraction, sponsored by Cardiac Success. Recruiting at 1 site in Poland. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Cardiac Success · Not applicable, Interventional, and Device feasibility

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.
Updated Oct 28, 2026Now RecruitingFirst site in Poland+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 275 studies in Heart Failure with a site in Poland — 56 open to participants now, 75 under way, 20 of them phase 3. Heart Failure · Poland.

Planned enrollment
216th of 225
10 · median 300
Started
2025
with 12 others
No phase
68 of 275
18 open now
Primary completion
2028-12
later than 61 of 74 live
Registered
214th of 275
by date

Among the 275 studies in Heart Failure with a site in Poland, this one is the 216th largest by planned enrollment of the 225 interventional ones that give a count, is one of 13 that started in 2025, is one of 68 with no phase, reaches primary completion later than 61 of the 74 other live ones, and was the 214th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

56 of the 275 studies in Heart Failure with a site in Poland are open now. Recruiting first, the newest first:

50 more — sign in →

All 56 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 275 studies in Heart Failure with a site in Poland, or all of them as a file.
02

Study summary

Prospective, multi-center, open-label clinical study of the feasibility and initial safety and performance of the Vsling™ in patients with heart failure (HF) with evidence of reduced left ventricular ejection fraction, associated with ventricular dilation.

03

Conditions studied

  • HFrEF - Heart Failure With Reduced Ejection Fraction

Browse trials for

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age≥ 18 and \< 85 years
  2. Left ventricular end diastolic diameter is greater than or equal to 55mm
  3. ≥20% and ≤40%
  4. FMR grade ≤ 2+ (≤ mild FMR) as defined by the guidelines of the American society of echocardiography (via a transthoracic or transesophageal echo)
  5. End-systolic Interpapillary muscle distance ≥ 20mm
  6. class II-IVa
  7. Cardiomyopathy of ischemic or non-ischemic origins
  8. Understands the nature of the study and procedure and able to provide written

Exclusion criteria

Exclusion Criteria:

  1. Any evidence of structural (chordal or leaflet) mitral lesions
  2. Ventricular tachycardia or ventricular fibrillation within 6 months prior to inclusion in this study
  3. Prior mitral valve repair or replacement
  4. ICD/CRT/cardiac pacemaker leads implanted within 3 months prior to inclusion in this study
  5. Clinical signs of cardiogenic shock within 30 days prior to inclusion in this study
  6. Anatomy that, in the opinion of the interventionalist, prevents safe passage of the Vsling™ catheter(s).
  7. Severe aortic stenosis
  8. Severe, massive, or torrential tricuspid regurgitation requiring surgical or transcatheter repair
  9. Known fixed pulmonary hypertension with PA systolic pressure >70 mmHg not responsive to vasodilator therapy
  10. ST segment elevation myocardial infarction within 30 days prior to inclusion in this study
  11. Congenital heart disease (except PFO, PDA or ASD)
  12. Heart Failure due to confirmed amyloid or other restrictive cardiomyopathies
  13. Chronic renal insufficiency defined by Creatinine ≥ 3.0 mg/dL or chronic renal replacement therapy
  14. Any therapeutic invasive cardiac procedure within 30 days prior to inclusion in the study
  15. Any cardiac surgery, within 3 months prior to inclusion in the study
  16. Cerebrovascular Accident (CVA) within 90 days prior to inclusion in this study
  17. Thrombocytopenia ( count\< 100,000/mm3) or thrombocytosis (Platelet count > 750,000/mm3)
  18. Body temperature >38°C within 3 days prior to index procedure
  19. Bleeding disorders or hypercoagulable state
  20. Active peptic ulcer or active gastrointestinal (GI) bleeding within 90 days of the scheduled implant
  21. to anticoagulants or antiplatelet agents
  22. Known allergy to stainless steel, nickel, titanium or contrast agents that cannot be adequately pre-medicated
  23. Known or contraindication to procedural medications which cannot be adequately managed medically
  24. Currently participating in another drug or device study that has not completed the primary endpoint or that clinically interferes with the endpoints of this study
  25. Co-morbid condition(s) that, in the opinion of the Investigator, limit to \< 12 months
  26. Co-morbid condition(s) that, in the opinion of the investigator, could limit the patient's ability to participate in the study, including compliance with follow-up requirements, or that could impact the scientific integrity of the study
  27. Pregnancy
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Vsling device

    Vsling device implantation

    Device: Vsling

Interventions

  • DeviceVsling

    Implantable ventricular repair device

06

What researchers measure

Primary outcomes

  1. Device related Serious Adverse Events (SAE)

    Device related Serious Adverse Events (SAE) within 30 days of the procedure: any SAE that has been determined by the safety monitor to be related to the Vsling™ implantation procedure or the Vsling™ device

    Time frame: 30 days

07

Study locations

1 of 1 sites recruiting
  • John Paull II Hospital
    Krakow, Poland
    Recruiting
    • Piotr Musialek, Prof. · Contactp.musialek@szpitaljp2.krakow.pl · +48 501 270 502
    • Lukasz Czyz, Dr. · Contact+48 695 570 097
    • Piotr Musialek, Prof. · Principal investigator
    • Lukasz Czyz, Dr. · Sub investigator
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Dec 2028, 47 months after the start.

Of 236 industry-sponsored interventional studies with no phase under Heart Failure, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 61. This study's planned 47 months is above that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: start Aug 2025 → Jan 2025, primary completion Mar 2026 → Dec 2028 and completion Dec 2029 → Dec 2031.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2023
First posted
Aug 21, 2023
StartActual
Jan 1, 2025was Aug 2025
Primary completionEst.
Dec 2028was Mar 2026
CompletionEst.
Dec 2031was Dec 2029
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 28, 2026
Sites
1 site added — first site in Poland
Show site
  • John Paull II Hospital · Krakow, Poland
Oct 28, 2026
Start date
Aug 2025→Jan 1, 2025 (actual)
Oct 28, 2026
Primary completion
Mar 2026→Dec 2028
Oct 28, 2026
Study completion
Dec 2029→Dec 2031
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in Poland
    Show site
    • John Paull II Hospital · Krakow, Poland
    Start date Aug 2025→Jan 1, 2025 (now actual)
    Primary completion Mar 2026→Dec 2028
    Study completion Dec 2029→Dec 2031
    + 6 other changes: identifiers, verification date, oversight details, conditions, data sharing statement and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06002386
Lead sponsor
Cardiac Success
Responsible party
Sponsor
First posted
Aug 21, 2023
Start date
Jan 1, 2025
Primary completion
Dec 2028 (estimated)
Completion
Dec 2031 (estimated)
Last update
Oct 28, 2026

Study contacts

Iris Yadin-Herling
Contact
iris.yh@cardiacsuccess.com
972546633352

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion